SOLICITATION NOTICE
A -- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement
- Notice Date
- 6/24/2022 1:24:26 PM
- Notice Type
- Solicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- ASPR OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE Washington DC 20201 USA
- ZIP Code
- 20201
- Solicitation Number
- BAA-20-100-SOL-0002
- Response Due
- 2/3/2023 2:00:00 PM
- Archive Date
- 02/18/2023
- Point of Contact
- Aarati Singal - Contract Specialist, DRIVe, Lara Emmons - Branch Chief, DRIVe
- E-Mail Address
-
aarati.singal@hhs.gov, lara.emmons@hhs.gov
(aarati.singal@hhs.gov, lara.emmons@hhs.gov)
- Description
- 6/24/2022 -��Please see Special Instructions 020 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these special instructions, BARDA is: 1. Adding the the following Area of Interest (AOI): � � AOI #14:� Healing Lungs: Simpler, Safer Lung Support for Severe ARDS Patients 3/31/2022 -��Please see Special Instructions 019 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 019, BARDA is: 1. Revising the descriptions of the following Areas of Interest (AOIs): � � AOI #12: �Mitigating Long-term Effects (MILE) of Respiratory Distress� 2. Update the closing dates for abstract submissions for the following AOIs: � � AOI #2: Infection Severity and Solving Sepsis � � AOI #5: ReDirect� � � AOI #12: Mitigating Long-term Effects (MILE) of Respiratory Distress 1/7/2022 - Please see Special Instructions 018 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 018, BARDA is: 1.�Revising the descriptions of the following Areas of Interest (AOIs): � � AOI #8: �Bringing Laboratory Testing to the Home � � AOI #9: �Digital Health Tools for Pandemic Preparedness � � AOI #11a: �Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 � � AOI #11b: �Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection 2. Adding AOI #13:� Endotyping for Host-Directed Therapeutics to the EZ-BAA. 3. Update the closing dates for abstract submissions for multiple AOIs under the EZ-BAA. 11/24/2021 - Please see Special Instructions 017 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 017, BARDA is hereby pausing ""AOI #6: Beyond the Needle"" until further notice. 11/10/2021 - Please see Special Instructions 016 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.��Under these Special Instructions 016, BARDA is re-opening ""AOI #5: ReDirect (Repurposing Drugs in Response to Chemical Threats)"" as part of its EZ-BAA (BAA-20-100-SOL-0002). 10/21/2021 -�Please see Special Instructions 015�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 015, BARDA is announcing the following as part of its EZ-BAA: Add ""AOI #12:�Mitigating Long-term Effects (MILE) of Respiratory Distress"" to the EZ-BAA.� Notify potential Respondents that any EZ-BAA contracts (above the micro-purchase threshold) awarded on or after November 14, 2021 will be subject to Class Deviation (2021-03) from the Federal Acquisition Regulation (FAR) Regarding Implementation of Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors. Remind potential Respondents that the following AOIs under the EZ-BAA are currently open and accepting abstract submissions: AOI #2:��Infection Severity and Solving Sepsis AOI #6:� Beyond the Needle AOI #8:� Bringing Laboratory Testing to the Home AOI #9:� Digital Health Tools for Pandemic Preparedness AOI #10:� Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens AOI #11a:��Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 AOI #11b:��Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection AOI #12:��Mitigating Long-term Effects (MILE) of Respiratory Distress 8/23/2021 - Please see Special Instructions 014 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.��Under these Special Instructions 014, BARDA is announcing the following as part of its EZ-BAA: Close Area of Interest (AOI) #1 supporting the Early Notification to Act, Control, and Treat (ENACT) program. Pause AOI #7 supporting the ImmuneChip+ program until further notice. Remind : AOI #8:��Bringing Laboratory Testing to the Home AOI #9:� Digital Health Tools for Pandemic Preparedness AOI #10:� Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens AOI #11a:�Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 AOI #11b:�Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection 3/4/2021 -�Please see Special Instructions 013�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 013, BARDA is now accepting abstract submissions for ""AOI #7: ImmuneChip+��as part of its EZ-BAA (BAA-20-100-SOL-0002). 10/22/2020 - Please see Special Instructions 012 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 012, BARDA is now accepting abstract submissions for ""AOI #1: ENACT �(Early Notification to Act, Control and Treat)� and ""AOI#2: Infection Severity & Solving Sepsis.��Additionally, �AOI #4.3:� Alternative Routes of Administration (AROA) for Vaccines� is now��AOI #6: Beyond the Needle.� 10/1/2020 - Please see Special Instructions 011�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.��Under these Special Instructions 011, BARDA is now accepting abstract submissions for�""Area of Interest #5: ReDIRECT (Repurposing Drugs In Response to Chemical Threats)"" as part of its EZ-BAA (BAA-20-100-SOL-0002). 7/9/2020 - Please see�Special Instructions 010 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.��Under these Special Instructions 010, BARDA is adding topic #4.1-E under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 6/29/2020 - Please see Special Instructions 009�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.��Under these Special Instructions 009, BARDA is revising topics #4.1-D and #4.3 immediately, and extending the closing date to 2359 HRS ET on 31 October 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 6/4/2020 - Amendment 001 to the EZ-BAA is now included as an attachment.� Amendment 001 revises Section C of the EZ-BAA.�� Please also see Special Instructions 008�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. �Under these Special Instructions 008, BARDA is revising topic�#4.3 immediately,�and closing topic�#4.4 at 1700 HRS ET on 05 June 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).� 5/12/2020 - Please see Special Instructions 007�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. �Under these Special Instructions 007, BARDA is closing topics #4.1-B and #4.1-C�under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).� 4/27/2020 -�Please see Special Instructions 006�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 006, BARDA is adding topic #4.1-D�under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).� 4/2/2020 -�Please see Special Instructions 005�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 005, BARDA is closing topic #4.1-A and revising topic #4.1-C�under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).� 3/18/2020 -�Please see Special Instructions 004�Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions 004, BARDA is closing topic #4.2 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).� 3/9/2020 -�Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002). 2/15/2020 - Please see Special Instructions 002 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.� Under these Special Instructions, BARDA�is adding a new topic under its temporary AOI #4:� 2019-nCoV as part of its EZ-BAA (BAA-20-100-SOL-0002). 2/3/2020 - Please see Special Instructions 001 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.��Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of its EZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. 2/3/2020 - See attachment(s).��This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) in the Office of Biomedical Advanced Research and Development Authority (BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal Acquisition Regulation (FAR). Abstract submissions selected for award are considered to be the result of full and open competition and in full compliance with 41 U.S.C. � 3301.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/b85d8eb17a6644bebfba54613bcb7340/view)
- Place of Performance
- Address: Washington, DC 20201, USA
- Zip Code: 20201
- Country: USA
- Zip Code: 20201
- Record
- SN06368315-F 20220626/220624230057 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |